(Q36849136)

16 August 2017

1 reference

title

Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

16 August 2017

main subject

0 references

inflammation

0 references

author name string

Arthur Barrie

series ordinal

1

1 reference

16 August 2017

Miguel Regueiro

series ordinal

2

1 reference

16 August 2017

publication date

1 November 2007

1 reference

Inflammatory Bowel Diseases

16 August 2017

published in

1 reference

16 August 2017

volume

13

1 reference

16 August 2017

issue

11

1 reference

16 August 2017

page(s)

1424-1429

1 reference

Review article: joint involvement in inflammatory bowel disease

16 August 2017

cites work

1 reference

Review article: skin complications associated with inflammatory bowel disease

21 January 2018

1 reference

Important cutaneous manifestations of inflammatory bowel disease

21 January 2018

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

21 January 2018

1 reference

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

21 January 2018

1 reference

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

21 January 2018

1 reference

Infliximab treatment in ankylosing spondylitis: an observational study

21 January 2018

1 reference

Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

21 January 2018

1 reference

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease.

21 January 2018

1 reference

Crohn's disease associated with Sweet's syndrome and Sjögren's syndrome treated with infliximab

21 January 2018

1 reference

The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study

21 January 2018

1 reference

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

Anti-TNF-alpha therapy for sight threatening uveitis

21 January 2018

1 reference

Retrospective case review of pediatric patients with uveitis treated with infliximab

21 January 2018

1 reference

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

Adalimumab in the therapy of uveitis in childhood

21 January 2018

1 reference

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

21 January 2018

1 reference

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

Musculoskeletal Manifestations in a Population-based Cohort of Inflammatory Bowel Disease Patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.20196

1 reference

16 August 2017

1 reference